Effects of mGlu2/3 Receptor Agonists Relevant to Schizophreniaa
Behaviorb | Neurochemistryc | Electrophysiologyd |
---|---|---|
a See (24, 33). | ||
b Results in traditional psychosis models (conditioned avoidance response, and pre-pulse inhibition of startle) have been negative or not seen across agents. | ||
c Focus has been on pharmacology in striatum (nucleus accumbens), prefrontal cortex, and limbic cortex/thalamus. | ||
d Focus has been on hippocampus, prefrontal cortex, amygdala, thalamocortical pathways. | ||
Decrease in NMDA antagonist induced behaviors (locomotion, cognitive impairment, attention) | Decrease in PCP-induced glutamate release | Decrease in glutamate-evoked EPSPs |
Decrease in amphetamine-induced behaviors (locomotion, rearing) | Decrease in PCP-induced release of 5HT, dopamine, and norepinephrine | Decrease in electrically evoked EPSPs |
Decrease in 5HT2A agonist induced behaviors (head-shaking) | Prevention of PCP-induced neuronal vacuolization and necrosis | Decrease in 5HT2A agonist evoked glutamate EPSPs |